Keros doses first patient in Phase 2 rinvatercept trial for Duchenne muscular dystrophy
Early data from the study are expected in the first half of 2027.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
Keros Therapeutics doses first patient in Phase 2 rinvatercept trial; initial data expected H1 2027
Keros Therapeutics dosed the first patient in its Phase 2 trial of rinvatercept for Duchenne muscular dystrophy and expects initial data in the first half of 2027.Key Highlights:Original SEC Filing: Keros Therapeutics, Inc. [ KROS ] - 8-K - Sep. 28, 2026This is an AI-powered summary. It may contain…